Are natural killer cells the key to treating Epstein-Barr virus-associated lymphoproliferative disorders?
Robertson
M J
MJ
Bone Marrow and Stem Cell Transplantation Program, Division of Hematology and Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA. mjrobert@iupui.edu
D000818:Animals; D004195:Disease Models, Animal; D020031:Epstein-Barr Virus Infections / Q000276:immunology / Q000628:therapy*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000276:immunology*; D008232:Lymphoproliferative Disorders / Q000276:immunology / Q000628:therapy*; D051379:Mice; D016513:Mice, SCID
D007376:Interleukin-2; D016178:Granulocyte-Macrophage Colony-Stimulating Factor